PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congressional Research Service
Version 00 · Introduced in House · Feb 7, 2025
Medicare IVIG Access Enhancement Act of 2025
This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)
People & committees
Rep. Smith, Adrian [R-NE-3] · R–NE
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Nov 5, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1143 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1143 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1143 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1143 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2025-02-07 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
The proposal would expand Medicare coverage for immune globulin treatment given into a vein at home, adding chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy to the coverage language beginning January 1, 2027. It would also allow payments for administering the treatment to differ by the condition being treated, through rules issued after public notice and an opportunity to comment.
Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program
(and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)
may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)
Section 1 would name the bill the Medicare IVIG Access Enhancement Act of 2025. IVIG refers to intravenous immune globulin.
This Act may be cited as the Medicare IVIG Access Enhancement Act of 2025.
Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program
Section 2(a) would amend two Medicare provisions that refer to primary immune deficiency diseases. Both additions would take effect beginning January 1, 2027: one adds treatment of the two named conditions, and the other expressly refers to diagnosed conditions.
Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended— (1) in subsection (s)(2)(Z), by inserting (and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy) after primary immune deficiency diseases; and (2) in subsection (zz), by inserting (or, beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy) after primary immune deficiency disease.
Section 2(b) would permit, rather than require, different administration payments depending on whether treatment is for primary immune deficiency disease, chronic inflammatory demyelinating polyneuropathy, or multifocal motor neuropathy. The Secretary would determine appropriate differences through rulemaking with public notice and an opportunity to comment. The proposed addition specifies no payment amounts.
(b) Authority for variance in payments Section 1842(o)(8) of the Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking) after of 2012.
The supplied actions snapshot, updated November 5, 2025, records introduction in the House on February 7, 2025, and referral that day to the Energy and Commerce and Ways and Means committees for consideration of provisions within their respective jurisdictions.
Source snapshot updated 2025-11-05T09:05:38Z.
2025-02-07: Introduced in House
2025-02-07: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
A closer look
Reviewed version: Introduced in House · 2025-02-07. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy change attached to appropriations was identified in the complete supplied introduced-text version. This conclusion does not extend to other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for particular recipients or places was identified in the complete supplied introduced-text version. This conclusion does not establish the absence of earmarks in other versions or accompanying materials.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No materially narrow carve-out, special exemption, or preferential exception was identified in the complete supplied introduced-text version. Ordinary coverage of intended program beneficiaries is not treated as preferential treatment. This conclusion does not extend to other versions or accompanying materials.
Full text preserved for this analysis. Legislative record snapshot: Nov 5, 2025. How PlainBill uses AI